Durata, Cubist Antibiotics Poised For Approval, Additional Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Dalbavancin may have to deal with a liver function issue, but both it and tedizolid receive overwhelming endorsements from FDA’s Anti-Infective Drugs Advisory Committee, setting the ABSSSI products up to be the first QIDP approvals.
You may also be interested in...
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.